STOCK TITAN

Agenus to Provide First Quarter 2024 Financial Report and Corporate Update

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Agenus Inc. will release its first quarter 2024 financial results on May 7, 2024. The company is a leader in developing novel immunological agents to treat various cancers. Agenus executives will discuss the results and provide a corporate update during a conference call and webcast at 8:30 a.m. ET.
Agenus Inc. pubblicherà i risultati finanziari del primo trimestre 2024 il 7 maggio 2024. L'azienda è leader nello sviluppo di nuovi agenti immunologici per il trattamento di vari tipi di cancro. I dirigenti di Agenus discuteranno i risultati e forniranno un aggiornamento aziendale durante una conferenza telefonica e un webcast alle 8:30 a.m. ET.
Agenus Inc. publicará sus resultados financieros del primer trimestre de 2024 el 7 de mayo de 2024. La compañía es líder en el desarrollo de agentes inmunológicos novedosos para tratar diversos tipos de cáncer. Los ejecutivos de Agenus discutirán los resultados y proporcionarán una actualización corporativa durante una teleconferencia y transmisión en web a las 8:30 a.m. ET.
Agenus Inc.는 2024년 첫 분기 재무 결과를 2024년 5월 7일에 발표할 예정입니다. 이 회사는 다양한 암을 치료하기 위한 새로운 면역 요법 개발을 선도하고 있습니다. Agenus의 경영진은 결과를 논의하고 오전 8시 30분 ET에 전화 회의 및 웹캐스트를 통해 회사 업데이트를 제공할 것입니다.
Agenus Inc. publiera ses résultats financiers du premier trimestre 2024 le 7 mai 2024. L'entreprise est un leader dans le développement de nouveaux agents immunologiques pour traiter divers cancers. Les dirigeants d'Agenus discuteront des résultats et fourniront une mise à jour corporative lors d'une conférence téléphonique et d'une diffusion web à 8:30 a.m. ET.
Agenus Inc. wird am 7. Mai 2024 die Finanzergebnisse des ersten Quartals 2024 veröffentlichen. Das Unternehmen ist führend in der Entwicklung neuer immunologischer Wirkstoffe zur Behandlung verschiedener Krebsarten. Die Führungskräfte von Agenus werden die Ergebnisse diskutieren und während eines Telefonkonferenz und eines Webcasts um 8:30 Uhr ET ein Unternehmensupdate geben.
Positive
  • None.
Negative
  • None.

LEXINGTON, Mass.--(BUSINESS WIRE)-- Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its first quarter 2024 financial results before the market opens on Tuesday, May 7, 2024. Agenus executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide a corporate update.

Conference Call:

To access dial-in numbers, please register here.

Conference ID: 73242

A live webcast and replay of the conference call will be accessible on the company’s website at https://investor.agenusbio.com/events-and-presentations and via https://events.q4inc.com/attendee/928123199.

About Agenus

Agenus is a leading immuno-oncology company targeting cancer and infectious diseases with a comprehensive pipeline of immunological agents. The company’s mission is to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus is headquartered in Lexington, MA. For more information, visit www.agenusbio.com or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels.

Forward-Looking Statements

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding a its botensilimab and balstilimab programs, expected regulatory timelines and filings, and any other statements containing the words "may," "believes," "expects," "anticipates," "hopes," "intends," "plans," "forecasts," "estimates," "will," “establish,” “potential,” “superiority,” “best in class,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Annual Report on Form 10-K for 2022, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

Investors

917-362-1370

investor@agenusbio.com



Media

917-362-1370

communications@agenusbio.com

Source: Agenus Inc.

FAQ

When will Agenus release its first quarter 2024 financial results?

Agenus will release its first quarter 2024 financial results before the market opens on Tuesday, May 7, 2024.

What does Agenus specialize in developing?

Agenus specializes in developing novel immunological agents to treat various cancers.

When will the conference call and webcast to discuss the financial results take place?

The conference call and webcast to discuss the financial results will take place at 8:30 a.m. ET on the morning of May 7, 2024.

Where can one access the live webcast and replay of the conference call?

The live webcast and replay of the conference call can be accessed on Agenus' website at https://investor.agenusbio.com/events-and-presentations and via https://events.q4inc.com/attendee/928123199.

Agenus Inc.

NASDAQ:AGEN

AGEN Rankings

AGEN Latest News

AGEN Stock Data

355.31M
17.69M
1.2%
59.18%
11.39%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
LEXINGTON

About AGEN

agenus is an immunology company discovering and developing novel checkpoint modulators, vaccines and adjuvants to treat cancer and other diseases. we are a dedicated group of scientists, researchers, biotechnologists, physicians, and businesspeople working together toward one goal: to discover and develop therapies that can unleash the innate power of the body’s immune system to treat and potentially cure hard-to-treat cancers and other diseases. our product candidates are designed to work by educating and activating the body’s immune system for a precise and potent attack on cancer. our strategy is to help unlock the potential of one of the most exciting breakthrough areas in cancer treatment in decades, and to develop single agent and combination immune-oncology therapies that can help save lives. our approaches are driven by three platform technologies, including: • our antibody platforms, including our proprietary retrocyte display™ and secant® technologies, and our antibody